Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
| Last: | $18.53 |
|---|---|
| Change Percent: | 0.16% |
| Open: | $18.668 |
| Close: | $18.50 |
| High: | $18.668 |
| Low: | $18.53 |
| Volume: | 241 |
| Last Trade Date Time: | 02/26/2026 10:26:30 am |
| Market Cap: | $1,508,423,728 |
|---|---|
| Float: | 49,696,926 |
| Insiders Ownership: | N/A |
| Institutions: | 16 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.oculis.com |
| Country: | CH |
| City: |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Oculis Holding AG Warrants (NASDAQ: OCSAW).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.